Malignancy as a comorbidity in rheumatic diseases

Rheumatology (United Kingdom)

Volumn 52, Issue 1, 2013, Pages 5-14

  Turesson, Carl ^a,b   Matteson, Eric L ^c  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Mayo Clinic   (United States)

Author keywords

Cancer; Comorbidity; Malignancy; Mortality; Myositis; RA; Rheumatic disease; Risk factors; SS; Treatment SLE

Indexed keywords

ABATACEPT; ACROLEIN; ADALIMUMAB; ANTIINFECTIVE AGENT; AZATHIOPRINE; BIOLOGICAL RESPONSE MODIFIER; CERTOLIZUMAB PEGOL; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; MESNA; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; STEROID; TOCILIZUMAB;

AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; BLADDER CARCINOMA; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER RISK; CARCINOGENESIS; CELL GROWTH; COLORECTAL CANCER; COMORBIDITY; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; HEPATOBILIARY SYSTEM CANCER; HODGKIN DISEASE; HOST; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; LIFE EXPECTANCY; LIVER CANCER; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CANCER; LYMPHOCYTOMA; LYMPHOMA; MARGINAL ZONE LYMPHOMA; MELANOMA; META ANALYSIS (TOPIC); MONITORING; MULTICENTER STUDY; MULTIPLE MYELOMA; MYOSITIS; NASOPHARYNX CARCINOMA; NON MELANOMA SKIN CANCER; NONHODGKIN LYMPHOMA; OVARY ADENOCARCINOMA; OVARY CANCER; PATHOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCLERODERMA; SCREENING; SMOKING; SPONDYLARTHRITIS; STANDARDIZED INCIDENCE RATIO; STOMACH ADENOCARCINOMA; STOMACH CANCER; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE ACTIVATION; UTERINE CERVIX CANCER; UTERUS CANCER; UTERUS CARCINOMA; VASCULITIS; VIRUS INFECTION; WALDENSTROEM MACROGLOBULINEMIA;

ANTIRHEUMATIC AGENTS; COMORBIDITY; HUMANS; NEOPLASMS; QUALITY OF LIFE; RHEUMATIC DISEASES; RISK FACTORS;

EID: 84871146837     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes189     Document Type: Review

References (97)

1. Bernatsky S, Boivin JF, Joseph L et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005;52:1481-90.
2. Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008;10: R45.
3. Kä llberg H. Rheumatoid arthritis and lung cancer: you probably heard it before. J Rheumatol 2008;35: 1695-6.
4. Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, Hunder GG. Cutaneous vasculitis and cancer: a clinical approach. Clin Exp Rheumatol 2000;18: 305-7.
5. Elandt K, Aletaha D. Treating rheumatic patients with a malignancy. Arthritis Res Ther 2011;13:223.
6. Shankaran V, Ikeda H, Bruce AT et al. IFN gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410: 1107-11.
7. Vajdic CM, McDonald SP, McCredie MR et al. Cancer incidence before and after kidney transplantation. JAMA 2006;296:2823-31.
8. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45.
9. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases, a meta-analysis. Arch Intern Med 2005;165: 2337-44.
10. Smedby KE, Hjalgrim H, Askling J et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin's lymphoma by subtype. J Natl Cancer Inst 2006; 98:51-60.
11. Baecklund E, Iliadou A, Askling J et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-71.
12. King JK, Costenbader KH. Characteristics of patients with systemic lupus erythematosus (SLE) and non-Hodgkin's lymphoma (NHL). Clin Rheum 2007;26:1491-4.
13. Landgren O, Engels EA, Pfeiffer RM et al. Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst 2006;98:1321-30.
14. National Board of Health and Welfare. Cancer Incidence in Sweden 2005. Stockholm, Sweden: National Board of Health and Welfare, 2007.
15. Dixon WG, Symmons DP, Lunt M et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007;56: 2896-904.
16. Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Influence of inflammatory polyarthritis on cancer incidence and survival: results from a community-based prospective study. Arthritis Rheum 2007;56:790-8.
17. Parikh-Patel A, White RH, Allen M, Cress R. Risk of cancer among rheumatoid arthritis patients in California. Cancer Causes Control 2009;20:1001-10.
18. Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 1978;31: 691-6.
19. Mellemkjaer L, Linet MS, Gridley G et al. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A:1753-7.
20. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004;50: 1740-51.
21. Baecklund E, Sundstrom C, Ekbom A et al. Lymphoma subtypes in patients with theumatoid arthritis: increased proportion of diffuse large B-cell lymphoma. Arthritis Rheum 2003;48:1543-50.
22. Kamel OW, Holly EA, van de Rijn M, Lele C, Sah A. A population based, case control study of non-Hodgkin's lymphoma in patients with rheumatoid arthritis. J Rheumatol 1999;26:1676-80.
23. Gridley G, Klippel JH, Hoover RN, Fraumeni JF Jr. Incidence of cancer among men with Felty syndrome. Ann Intern Med 1994;120:35-9.
24. Kassan SS, Thomas TL, Moutsopolos HM et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978; 89:888-92.
25. Lamy T, Loughran TP Jr. Current concepts: large granular lymphocyte leukemia. Blood Rev 1999;13:230-40.
26. Kauppi M, Pukkala E, Isomaki H. Excess risk of lung cancer in patients with rheumatoid arthritis. J Rheumatol 1996;23:1484-5.
27. Heliö vaara M, Aho K, Aromaa A, Knecht P, Reumnanen A. Smoking and the risk of rheumatoid arthritis. J Rheumatol 1993;20:1830-5.
28. Bergström U, Jacobsson LT, Nilsson JÅ, Berglund G, Turesson C. Pulmonary dysfunction, smoking, socioeconomic status and the risk of developing rheumatoid arthritis. Rheumatology 2011;50:2005-13.
29. Khurana R, Wolf R, Berney S et al. Risk of development of lung cancer is increased in patients with rheumatoid arthritis: a large case control study in US veterans. J Rheumatol 2008;35:1704-8.
30. Hemminki K, Li X, Sundquist K, Sundquist J. Cancer risk in hospitalized rheumatoid arthritis patients. Rheumatology 2008;47:698-701.
31. Berkel H, Holcombe RF, Middlebrooks M, Kannan K. Nonsteroidal anti-inflammatory drugs and colorectal cancer. Epidemiol Rev 1996;18:205-17.
32. Bernatsky S, Boivin J-F, Clarke A, Rajan R. Cancer risk in systemic lupus erythematosus: a meta-analysis. Arthritis Rheum 2001;44(Suppl. 9):S244.
33. Bernatsky S, Ramsey-Goldman R, Rajan R et al. Non-Hodgkin's lymphoma in systemic lupus erythematosus. Ann Rheum Dis 2005;64:1507-9.
34. Lö fstrom B, Backlin C, Sundstrom C, Ekbom A, Lundberg IE. A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study. Ann Rheum Dis 2007;66:1627-32.
35. Parikh-Patel AR, White H, Allen M, Cress R. Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. Cancer Causes Control 2008;19: 887-994.
36. Antonelli A, Mosca M, Fallahi P et al. Thyroid cancer in systemic lupus erythematosus: a case-control study. J Clin Endocrinol Metab 2010;95:314-8.
37. Xu Y, Wiernik PH. Systemic lupus erythematosus and B-cell hematologic neoplasm. Lupus 2001;10:841-50.
38. Bernatsky S, Clarke A, Ramsey-Goldman R et al. Hormonal exposures and breast cancer in a sample of women with systemic lupus erythematosus. Rheumatology 2004;43:1178-81.
39. Bernatsky SR, Cooper GS, Mill C et al. Cancer screening in patients with systemic lupus erythematosus. J Rheumatol 2006;33:45-9.
40. Dhar JP, Kmak D, Bhan R et al. Abnormal cervicovaginal cytology in women with lupus: a retrospective cohort study. Gynecol Oncol 2001;82:4-6.
41. Gayed M, Bernatsky S, Ramsey-Goldman R, Clarke A, Gordon C. Lupus and cancer. Lupus 2009;18:479-85.
42. Bengtsson AA, Rylander L, Hagmar L, Nived O, Sturfelt G. Risk factors for developing systemic lupus erythematosus-a case-control study from southern Sweden. Rheumatology 2002;41:563-71.
43. Lö fstrom B, Backlin C, Sundstrom C et al. Myeloid leukemia in systemic lupus erythematosus: a nested case-control study based on Swedish registers. Rheumatology 2009;48:1222-6.
44. Sutcliffe N, Inanc M, Speight P, Isenberg D. Predictors of lymphoma development in primary Sjö gren's syndrome. Semin Arthritis Rheum 1998;28:80-7.
45. Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjö gren's syndrome: a prospective cohort study. Arthritis Rheum 2004;50: 1262-9.
46. Voulgarelis M, Moutsopoulos HM. Mucosa-associated lymphoid tissue lymphoma in Sjogren's syndrome: risks, management, and prognosis. Rheum Dis Clin N Am 2008; 34:921-33.
47. Theander E, Henriksson G, Ljungberg O et al. Lymphoma and other malignancies in primary Sjö gren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006;65:796-803.
48. Pertovaara M, Pukkala E, Laippala P, Miettinen A, Pasternack A. A longitudinal cohort study of Finnish patients with primary Sjö gren's syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis 2001;60:467-72.
49. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjö gren's syndrome. Arthritis Rheum 2002;46:741-7.
50. Ramos-Casals M, Brito-Zerón P, Yagüe J et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome. Rheumatology 2005;44:89-94.
51. Theander E, Vasaitis L, Baecklund E et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjö gren's syndrome. Ann Rheum Dis 2011;70: 1363-8.
52. Rosenthal AK, McLaughlin JK, Linet MS, Persson I. Scleroderma and malignancy: an epidemiological study. Ann Rheum Dis 1993;52:531-3.
53. Chatterjee S, Dombi GW, Severson RK, Mayes MD. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum 2005;52:2415-24.
54. Derk CT, Rasheed M, Artlett CM, Jimenez SA. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol 2006;33:1113-6.
55. Wipff J, Allanore Y, Soussi F et al. Prevalence of Barrett's esophagus in systemic sclerosis. Arthritis Rheum 2005;52: 2882-8.
56. Rosenthal AK, McLaughlin JK, Gridley G, Nyrén O. Incidence of cancer among patients with systemic sclerosis. Cancer 1995;76:910-4.
57. Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. N Engl J Med 1992;326:363-7.
58. Buchbinder F, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy. Ann Intern Med 2001;134:1087-95.
59. Zantos D, Zhang Y, Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol 1994;21:1855-9.
60. Huang YL, Chen YJ, Lin MW et al. Malignancies associated with dermatomyositis and polymyositis in Taiwan: a nationwide population-based study. Br J Derm 2009;161: 854-60.
61. Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County. Arch Dermatol 2010;146:26-30.
62. Casciola-Rosen L, Nagaraju K, Plotz P et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005;201: 591-601.
63. Faurschou M, Mellemkjaer L, Sorensen IJ et al. Cancer preceding Wegener's granulomatosis: a case-control study. Rheumatology 2009;48:421-4.
64. Kermani TA, Schä fer VS, Crowson CS et al. Malignancy risk in patients with giant cell arteritis: a population-based cohort study. Arthritis Care Res 2010;62:149-54.
65. Rohekar S, Tom B, Hassa A et al. Prevalence of malignancy in psoriatic arthritis. Arthritis Rheum 2007;58:82-7.
66. Feltelius N, Ekbom A, Blomqvist P. Cancer incidence among patients with ankylosing spondylitis in Sweden 1965-95: a population based cohort study. Ann Rheum Dis 2003;62:1185-8.
67. Oldroyd J, Schachna L, Buchbinder R et al. Ankylosing spondylitis patients commencing biologic therapy have high baseline levels of comorbidity: a report from the Australian Rheumatology Association database. Int J Rheum 2009;2009:268569.
68. Askling J, Klareskog L, Blomqvist P, Fored M, Feltelius N. Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study. Ann Rheum Dis 2006;65:1184-7.
69. Bernatsky S, Lee JL, Rahme E. Non-Hodgkin's lymphoma-meta-analyses of the effects of corticosteroids and non-steroidal anti-inflammatories. Rheumatology 2007;46: 690-4.
70. Radis CD, Kahl LE, Baker GL et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival in patients with rheumatoid arthritis. A 20-year follow-up study. Arthritis Rheum 1995;38:1120-7.
71. Hellgren K, Iliadou A, Rosenquist R et al. Rheumatoid arthritis, treatment with corticosteroids and risk of malignant lymphomas: results from a case-control study. Ann Rheum Dis 2010;69:654-9.
72. Matteson EL, Hickey AR, Maguire L et al. Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry: Rheumatoid Arthritis Azathioprine Registry Steering Committee. J Rheumatol 1991;18:809-14.
73. Silman AJ, Petrie J, Hazleman B, Evans SJ. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20-year follow-up study. Ann Rheum Dis 1988;47:988-92.
74. Nero P, Rahman A, Isenberg DA. Does long-term treatment with azathioprine predispose to malignancy and death in patients with systemic lupus erythematosus? Ann Rheum Dis 2004;63:325-6.
75. Georgescu L, Quinn GC, Schwartzman S, Paget SA. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum 1997;26:794-804.
76. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation and cancer. Cell 2010;140:883-99.
77. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation and cancer. J Clin Invest 2007; 117:1175-83.
78. Perkins ND. NF-kB: tumor promotor or suppressor? Trends Cell Biol 2004;14:64-9.
79. Bongartz T, Sutton AJ, Sweeting MJ et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
80. Bongartz T, Warren FC, Mines D et al. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomized controlled trials. Ann Rheum Dis 2009;68:1177-83.
81. Setoguchi S, Solomon DH, Weinblatt ME et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006;54: 2757-64.
82. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007;56:2886-95.
83. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009;68:1136-45.
84. Askling J, van Vollenhoven RF, Granath F et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum 2009;60: 3180-9.
85. Strangfeld A, Hierse F, Rau R et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German Biologics register RABBIT. Arthritis Res Ther 2010;12:R5.
86. Askling J, Fahrbach K, Nordstrom B et al. Cancer risk with tumor necrosis factor (TNF) alpha inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011;20:119-30.
87. DixonWG, Watson KD, Lunt M et al. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res 2010;62:775-63.
88. Le Blay P, Mouterde G, Barnetche T, Morel J, Combe B. Short term risk of total malignancy and nonmelanoma skin cancer with certolizumab or golimumab in patients with rheumatoid arthritis: meta-analysis of randomized controlled trials. J Rheumatol 2012;39:712-5.
89. Burmester GR, Mease P, Dijkmans BA et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009;68:1863-9.
90. Mariette X, Matucci-Cerinic M, Pavelka K et al. Malignancies associated with tumor necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011;70:1895-904.
91. Solomon DH, Mercer E, Kavanaugh A. Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis. Arthritis Rheum 2012;64:21-32.
92. Van Vollenhoven RF, Emery P, Bingham CO 3rd et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 2010;37:558-67.
93. Singh JA, Furst DE, Bharat A et al. 2012 Update of the 2008 American College of Rheumatology (ACR) Recommendations for the use of disease-modifying anti-rheumatic drugs and biologics in the treatment of rheumatoid arthritis (RA). Arthritis Care Res 2012;64:625-39.
94. Simon TA, Smitten AL, Franklin J et al. Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis 2009;68:1819-26.
95. Schiff MH, Kremer JM, Jahreis A. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011;13: R141.
96. Fleischmann RM, Tesser J, Schiff MH et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:1006-12.
97. Nannini C, Cantini F, Niccoli L et al. Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures? Arthritis Rheum 2009;61:801-12.